Update on typical and atypical antipsychotic drugs

Herbert Y Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview article

189 Citations (Scopus)

Abstract

Antipsychotic drugs (APDs) are best classified as typical or atypical.The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD). The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.TDincreases the death rate and can be minimized by limiting use of typical APDs. Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for reduction of suicide, and for improving longevity. The typical and atypical APDs do not differ in improving psychopathology in non-TRS. The atypicals vary in metabolic side effects: some have little burden. Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS. Overall, choosing among the atypical APDs as firstline treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.

Original languageEnglish (US)
Pages (from-to)393-406
Number of pages14
JournalAnnual Review of Medicine
Volume64
DOIs
StatePublished - Jan 14 2013

Fingerprint

Antipsychotic Agents
Schizophrenia
Aptitude
Clozapine
Cholinergic Antagonists
Psychopathology
Synaptic Transmission
Psychotic Disorders
Suicide
Cognition
Therapeutics
Modulation
Data storage equipment
Mortality
Pharmaceutical Preparations

Keywords

  • antipsychotic
  • clozapine
  • cognition
  • extrapyramidal
  • metabolic
  • psychosis
  • schizophrenia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{89763e597de14cb9a769ed390b2b6917,
title = "Update on typical and atypical antipsychotic drugs",
abstract = "Antipsychotic drugs (APDs) are best classified as typical or atypical.The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD). The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.TDincreases the death rate and can be minimized by limiting use of typical APDs. Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for reduction of suicide, and for improving longevity. The typical and atypical APDs do not differ in improving psychopathology in non-TRS. The atypicals vary in metabolic side effects: some have little burden. Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS. Overall, choosing among the atypical APDs as firstline treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.",
keywords = "antipsychotic, clozapine, cognition, extrapyramidal, metabolic, psychosis, schizophrenia",
author = "Meltzer, {Herbert Y}",
year = "2013",
month = "1",
day = "14",
doi = "10.1146/annurev-med-050911-161504",
language = "English (US)",
volume = "64",
pages = "393--406",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

Update on typical and atypical antipsychotic drugs. / Meltzer, Herbert Y.

In: Annual Review of Medicine, Vol. 64, 14.01.2013, p. 393-406.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Update on typical and atypical antipsychotic drugs

AU - Meltzer, Herbert Y

PY - 2013/1/14

Y1 - 2013/1/14

N2 - Antipsychotic drugs (APDs) are best classified as typical or atypical.The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD). The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.TDincreases the death rate and can be minimized by limiting use of typical APDs. Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for reduction of suicide, and for improving longevity. The typical and atypical APDs do not differ in improving psychopathology in non-TRS. The atypicals vary in metabolic side effects: some have little burden. Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS. Overall, choosing among the atypical APDs as firstline treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.

AB - Antipsychotic drugs (APDs) are best classified as typical or atypical.The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD). The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.TDincreases the death rate and can be minimized by limiting use of typical APDs. Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for reduction of suicide, and for improving longevity. The typical and atypical APDs do not differ in improving psychopathology in non-TRS. The atypicals vary in metabolic side effects: some have little burden. Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS. Overall, choosing among the atypical APDs as firstline treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.

KW - antipsychotic

KW - clozapine

KW - cognition

KW - extrapyramidal

KW - metabolic

KW - psychosis

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84873045013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873045013&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-050911-161504

DO - 10.1146/annurev-med-050911-161504

M3 - Review article

C2 - 23020880

AN - SCOPUS:84873045013

VL - 64

SP - 393

EP - 406

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -